

Mayne pharma to expand its Greenville facility; add 110 jobs

28 August 2015 | News | By BioSpectrum Bureau

Mayne pharma to expand its Greenville facility; add 110 jobs



Singapore: Australia-based specialty pharmaceutical company, Mayne pharma, recently announced plans to invest \$65 million at its facility in Greenville and add 110 jobs in the next five years. Mayne pharma develops and manufactures branded and generic products globally, in addition to providing contract development and manufacturing services.

Mayne, which already has 350 employees in Greenville, will pay average annual salaries of \$60,000 to the new hires, according to a recent announcement from the office of Gov. Pat McCrory. Mayne pharma acquired the Greenville facility in 2012. Expansion plans include 126,000 square feet of new FDA-compliant space for use in large-scale oral and solid-dose manufacturing.

Mayne will receive up to \$550,000 in incentives from the state's One North Carolina Fund if it meets its hiring and investment targets. One NC grants also require a matching grant from local governments.

The new manufacturing facility in Greenville, which is expected to be fully operational in 2018, will manufacture and package both Mayne brand specialty drugs and generic drugs, as well as providing contract manufacturing services for clients.

Mr Stefan Cross, president of Mayne Pharma USA, said in a statement, "Expanding our Greenville operations solidifies Mayne Pharma's aspirations in the U.S. market, while building our talented workforce. Once operational, we can take on new and larger products, specifically those that rely upon our company's drug-delivery and potent handling expertise."